Key Financial Data Of Group

Modalis Therapeutics Corporation - Filing #7312187

Concept 2024-01-01 to
2024-06-30
As at
2024-06-30
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-06-30
As at
2023-06-30
Key financial data of group
Business results of group
Ordinary profit (loss)
-780,152,000 JPY
-2,351,788,000 JPY
-995,474,000 JPY
Profit (loss) attributable to owners of parent
-780,946,000 JPY
-2,391,821,000 JPY
-1,033,228,000 JPY
Comprehensive income
-772,145,000 JPY
-2,400,981,000 JPY
-1,034,904,000 JPY
Net assets
1,112,727,000 JPY
1,380,422,000 JPY
2,532,501,000 JPY
Total assets
1,409,675,000 JPY
2,025,925,000 JPY
2,855,661,000 JPY
Basic earnings (loss) per share
-21.98
-77.24
-34.24
Diluted earnings per share
Equity-to-asset ratio
0.778 xbrli:pure
0.668 xbrli:pure
0.880 xbrli:pure
Net cash provided by (used in) operating activities
-931,410,000 JPY
-2,254,466,000 JPY
-979,332,000 JPY
Net cash provided by (used in) investing activities
-188,000 JPY
-39,699,000 JPY
-37,830,000 JPY
Net cash provided by (used in) financing activities
256,143,000 JPY
1,216,451,000 JPY
615,005,000 JPY
Cash and cash equivalents
1,278,281,000 JPY
1,883,437,000 JPY
2,591,391,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.